Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
1.420
-0.040 (-2.74%)
Jul 11, 2025, 4:00 PM - Market closed
Oragenics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
1.17M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
OGEN News
- 9 days ago - Oragenics Completes Approximately $16.5 Million Offering - GlobeNewsWire
- 10 days ago - Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewsWire
- 2 months ago - Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) - GlobeNewsWire